echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Feed Industry News > Ministry of Agriculture and Rural Affairs: Clinical trials of swine fever vaccine in Africa are progressing well

    Ministry of Agriculture and Rural Affairs: Clinical trials of swine fever vaccine in Africa are progressing well

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Reporter 10 from the Ministry of Agriculture and Rural Affairs of China was informed that the same day held the Chinese Academy of Agricultural Sciences 2017-2020 major scientific research progress conference announced that by the Harbin Veterinary Research Institute independently developed the environmental release of African swine fever vaccine and clinical trials are progressing smoothlyEsd
    After the outbreak of African swine fever in China, according to the deployment of the Ministry of Agriculture and Rural Affairs, the Chinese Academy of Agricultural Sciences has made every effort to organize the prevention and control of African swine plague, and has completed the research and industrialization of the African swine fever vaccine creation laboratory research and industrialization intermediate trial work, a gene-deficit vaccine shows good safety and effectivenessThe vaccine strain was approved for environmental release trials in December 2019 through a national reviewEsd
    Since March this year, the team has overcame local extreme low temperatures and the outbreak of new crown pneumonia to carry out environmental release trials of vaccine strainsUp to now, the growth of vaccinated piglets is in good condition, no abnormal clinical condition, the vaccinated sow is in good condition, no abnormal clinical performance, no abnormal ity, no abortion, immune pig no vaccine toxic emissions, no level transmission, after immunization, most of the sows have given birth, the immune group and control group birth, stillbirth rate is not significantdifference, piglet growth is goodEsd
    In March 2020, the vaccine was approved for clinical trials of veterinary biological products by the Ministry of Agriculture and Rural AffairsAccording to the clinical trial plan, in early April, early May and early June this year, inHeilongjiang, Henan and Xinjiangthree bases to start clinical trials of vaccines, a total of about 3000 pigsUp to now, the growth of immune piglets is in good condition, there are no obvious clinical adverse reactions; by caesarean section of the vaccinated pigs, there were no obvious pathological changes in the , no vaccine emissions, no level-spreading , and so far, the overall death elimination rate of was less than 1% , and there was no significant difference between the immune group and the control group Esd
      At present, the clinical effectiveness of the vaccine trial is under way Next, the Chinese Academy of Agricultural Sciences will accelerate the development of vaccines in accordance with the requirements of animal vaccine biosafety management and veterinary drug evaluation Esd
    (Author: Chen Yan) reporter 10 from the Ministry of Agriculture and Rural Affairs of China was informed that the same day held the Chinese Academy of Agricultural Sciences 2017-2020 major scientific research progress conference announced that by the Harbin Veterinary Research Institute independently developed the environmental release of African swine fever vaccine and clinical trials are progressing smoothly Esd
      After the outbreak of African swine fever in China, according to the deployment of the Ministry of Agriculture and Rural Affairs, the Chinese Academy of Agricultural Sciences has made every effort to organize the prevention and control of African swine plague, and has completed the research and industrialization of the African swine fever vaccine creation laboratory research and industrialization intermediate trial work, a gene-deficit vaccine shows good safety and effectiveness The vaccine strain was approved for environmental release trials in December 2019 through a national review Esd
      Since March this year, the team has overcame local extreme low temperatures and the outbreak of new crown pneumonia to carry out environmental release trials of vaccine strains Up to now, the growth of vaccinated piglets is in good condition, no abnormal clinical condition, the vaccinated sow is in good condition, no abnormal clinical performance, no abnormal ity, no abortion, immune pig no vaccine toxic emissions, no level transmission, after immunization, most of the sows have given birth, the immune group and control group birth, stillbirth rate is not significantdifference, piglet growth is good Esd
      In March 2020, the vaccine was approved for clinical trials of veterinary biological products by the Ministry of Agriculture and Rural Affairs According to the clinical trial plan, in early April, early May and early June this year, in Heilongjiang, Henan and Xinjiang three bases to start clinical trials of vaccines, a total of about 3000 pigs Up to now, the growth of immune piglets is in good condition, there are no obvious clinical adverse reactions ; by caesarean section of the vaccinated pigs, there were no obvious pathological changes in the , no vaccine emissions, no level-spreading , and so far, the overall death elimination rate of was less than 1% , and there was no significant difference between the immune group and the control group Esd
      At present, the clinical effectiveness of the vaccine trial is under way Next, the Chinese Academy of Agricultural Sciences will accelerate the development of vaccines in accordance with the requirements of animal vaccine biosafety management and veterinary drug evaluation Esd
    (Author: Chen) related to the "African Swine Fever Vaccine, Clinical Trials" article: Recommended Topics: News Click: Top Picture News: News Review Stakes: Seven-Word Forum:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.